Change on the Board of Directors of the Zur Rose Group Montag, 04. März 2019 - 07:00

Zur Rose Group AG / Key word(s): Personnel
Change on the Board of Directors of the Zur Rose Group

04.03.2019 / 07:00

---------------------------------------------------------------------------

Press release

Change on the Board of Directors of the Zur Rose Group

Vanessa Frey and Dr. Heinz O. Baumgartner have decided not to stand again
for re-election to the Zur Rose Group's Board of Directors at the next
Annual General Meeting. This move is associated with differences of opinion
about how and how fast the growth strategy should be implemented.

Both the Board of Directors and Group Management thank Vanessa Frey and
Heinz Baumgartner for their dedicated service in the highest governing body
of the Zur Rose Group.

The Board of Directors is seeking to strengthen the Board further with tech
expertise and commercial experience. It will nominate two suitably qualified
candidates for election at the Annual General Meeting to be held on 23 May
2019.

Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Corporate Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Financial Calendar
21 March 2019 Annual Results 2018
17 April 2019 Q1/2019 Trading Update
23 May 2019 Annual General Meeting
21 August 2019 2019 Half-Year Results
23 October 2019 Q3/2019 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of
the leading medical wholesalers in Switzerland. With its business model, it
offers high-quality, safe and cost-effective pharmaceutical care and thus
contributes to reducing healthcare costs. It is also characterized by the
continuous further development of digital services in the field of drug
management and actively promotes its positioning as a comprehensive,
integrated cross-service healthcare platform. The creation of added value
and a pronounced patient orientation make the Group an important strategic
partner for service providers, cost units and industry.

The Zur Rose Group is internationally present with strong brands, including
Germany's best-known pharmacy brand DocMorris. The company employs over
1,000 people at various locations and generated a turnover of CHF 1,207
million in the 2018 financial year. The shares of Zur Rose Group AG are
listed on the SIX Swiss Exchange (securities number 4261528, ISIN
CH0042615283, ticker ROSE). The CHF 115 million corporate bond issued in
July 2018 is also listed on the SIX Swiss Exchange (securities number
42146044, ISIN CH0421460442, ticker ZRO18). Further information at
zurrosegroup.com